The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksImperial Innovations Group Regulatory News (IVO)

  • There is currently no data for IVO

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8.5 (EPT/RI) - Touchstone Innovations Plc

13 Sep 2017 09:33

RNS Number : 6221Q
Numis Securities Limited
13 September 2017
 

FORM 8.5 (EPT/RI)

 

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY

Rule 8.5 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Name of exempt principal trader:

Numis Securities Limited

(b) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

 

Touchstone Innovations PLC

 

(c) Name of the party to the offer with which exempt principal trader is connected:

Sponsor, Broker and Joint Financial Adviser to IP Group PLC

 

(d) Date dealing undertaken:

12/09/2017

(e) In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to this offer?

If it is a cash offer or possible cash offer, state "N/A"

 

Yes

IP Group PLC

 

 

2. DEALINGS BY THE EXEMPT PRINCIPAL TRADER

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

The currency of all prices and other monetary amounts should be stated.

 

(a) Purchases and sales

 

Class of relevant security

Purchases/ sales

 

Total number of securities

Highest price per unit paid/received

Lowest price per unit paid/received

3 1/33p ordinary

 

Purchase

N/A

N/A

N/A

3 1/33p ordinary

 

Sale

2,000

255.00 GBX

255.00 GBX

 

(b) Cash-settled derivative transactions

 

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

 

(c) Stock-settled derivative transactions (including options)

 

(i) Writing, selling, purchasing or varying

 

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

 

(ii) Exercise

 

Class of relevant security

Product description

e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

 

 

 

(d) Other dealings (including subscribing for new securities)

 

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

 

 

 

3. OTHER INFORMATION

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

None

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

None

 

 

Date of disclosure:

13/09/2017

Contact name:

Jessica Meta

Telephone number:

0207 260 1330

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

 

The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
FERGIGDCBXBBGRX
Date   Source Headline
12th Dec 20123:02 pmRNSResult of AGM
16th Nov 20127:00 amRNSVeryan CE Mark approval for BioMimics 3D Stent
5th Nov 20127:00 amRNSPortfolio companies receive government funding
19th Oct 201210:00 amRNSGrant of share options
5th Oct 20127:00 amRNSFull year results
4th Oct 20127:00 amRNSCircassia initiates phase III trial
26th Sep 20127:00 amRNSPsiOxus commences clinical trial
20th Sep 201212:39 pmRNSNotice of Results
13th Sep 20123:25 pmRNSCircassia appoints Dr Brett Haumann as CMO
12th Sep 201211:35 amRNSAward Win
6th Sep 20127:00 amRNSInvestment in Cambridge technology company
1st Aug 20123:58 pmRNSDirector Dealings
23rd Jul 20127:00 amRNSInvestment in portfolio company
11th Jul 20122:50 pmRNSVeryan Medical appoints new COO and NEDs
9th Jul 20127:00 amRNS£22m funding round for PsiOxus Therapeutics
5th Jul 20125:20 pmRNSGrant of share options
27th Jun 20128:12 amRNSAbingdon Health acquires controlling stake
18th Jun 20127:00 amRNSInvestment in Oxford healthcare company
12th Jun 20127:00 amRNSInvestment in Cambridge technology company
31st May 20129:36 amRNSDirector/PDMR Shareholding
29th May 201210:05 amRNSPolytherics expands relationship with Pro Bono Bio
24th May 20127:00 amRNSDirector Dealings
1st May 20123:04 pmRNSDirector Dealings
23rd Apr 20127:00 amRNSHalf year results
26th Mar 20123:51 pmRNSNotice of Results
26th Mar 20127:00 amRNSInvestment in portfolio company
21st Mar 20127:00 amRNSDirectorate Change
8th Mar 20127:00 amRNSCircassia Phase II Clinical Trial Success
13th Feb 20127:00 amRNSInvestment in portfolio company
14th Dec 20115:27 pmRNSResult of AGM
6th Dec 20117:00 amRNSInvestment in new start-up
5th Oct 20117:00 amRNSFinal Results
27th Sep 20118:56 amRNSNotice of Results
7th Sep 20117:00 amRNSFurther investment in portfolio company
25th Aug 20117:00 amRNSInvestment in Cambridge company
22nd Aug 20117:00 amRNSInvestment in new company
3rd Aug 20117:00 amRNSInvestment in portfolio company
20th Jul 20117:00 amRNSInvestment in Stanmore
22nd Jun 20119:35 amRNSPortfolio company joint venture
19th Apr 20117:00 amRNSCircassia raises £60m
19th Apr 20117:00 amRNSHalf Yearly Report
30th Mar 201112:41 pmRNSNotice of Results
7th Feb 20116:00 pmRNSNotification of major interest in shares
3rd Feb 20118:16 amRNSDirectors' Dealings
27th Jan 20112:56 pmRNSNotification of major interest in shares
27th Jan 20112:51 pmRNSNotification of major interest in shares
26th Jan 20116:01 pmRNSNotification of major interest in shares
25th Jan 20116:03 pmRNSDirectors' Dealings
25th Jan 20115:40 pmRNSResults of Rump placing
24th Jan 20114:11 pmRNSVoting rights & share capital

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.